By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
News for IndiaNews for IndiaNews for India
  • Home
  • Posts
  • Search Page
  • About us
Reading: Corona Remedies IPO vs Wakefit Innovations IPO vs Nephrocare IPO: What GMP signals about listing pop? | Stock Market News
Share
Font ResizerAa
News for IndiaNews for India
Font ResizerAa
  • Economics
  • Business
  • Home
  • Categories
    • Business
    • Economics
  • About us
  • Sitemap
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
News for India > Business > Corona Remedies IPO vs Wakefit Innovations IPO vs Nephrocare IPO: What GMP signals about listing pop? | Stock Market News
Business

Corona Remedies IPO vs Wakefit Innovations IPO vs Nephrocare IPO: What GMP signals about listing pop? | Stock Market News

Last updated: December 10, 2025 11:31 am
5 months ago
Share
SHARE


Contents
Nephrocare IPO GMP todayCorona Remedies IPO GMP todayWakefit IPO GMP today

The primary market is currently experiencing heightened activity, with six IPOs open for investment, notably including the Corona Remedies IPO, Wakefit Innovations IPO, and Nephrocare IPO in focus. Wednesday’s trading session stands out as particularly vibrant, featuring the successful debut of the Meesho IPO, Aequs IPO, and Vidya Wires IPO in the Indian stock market.

As we look ahead, the IPOs for Wakefit Innovations and Corona Remedies are approaching their final days, creating opportunities for investors. Simultaneously, the Nephrocare Health Services IPO and Park Medi World IPO are preparing to make their entrance onto D-Street, adding to the excitement in the market.

Also Read | Nephrocare Health IPO Day 1 LIVE: Issue opens for subscription; GMP flat

Let’s take a look at the grey market premium (GMP) trends and details:

Nephrocare IPO GMP today

Nephrocare IPO GMP today or grey market premium was ₹0, which meant shares were trading at their issue price of ₹460 with no premium or discount in the grey market according to chittorgarh.com

Nephrocare Health Services, based in Hyderabad, launched its ₹871-crore IPO for public subscription starting on December 10 and ending on December 12. The company has set a price range of ₹438-460 per share for this IPO, which gives it a valuation exceeding ₹4,600 crore.

Nephrocare IPO comprises a fresh issue of shares totaling ₹353.4 crore and an Offer For Sale (OFS) of 1.12 crore shares worth ₹517.6 crore at the upper price point, bringing the overall issue size to ₹871 crore.

The book-running lead managers for the issue are ICICI Securities, Ambit, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) Private Ltd., while Kfin Technologies Ltd. serves as the issue’s registrar.

Corona Remedies IPO GMP today

Corona Remedies IPO GMP today is ₹265. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Corona Remedies share price is indicated at ₹1,327 apiece, which is 24.95% higher than the IPO price of ₹1,062.

Considering the grey market trends from the past nine sessions, today’s IPO GMP is showing an upward trajectory and is anticipated to have a solid listing. The lowest GMP recorded is ₹0.00, while the highest GMP stands at ₹365, as per expert opinions.

Also Read | Corona Remedies IPO Day 3: Here’s subscription status, GMP – apply or not?
Corona Remedies IPO

Wakefit IPO GMP today

Wakefit IPO GMP today is ₹2. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Wakefit is indicated at ₹197 apiece, which is 1.03% higher than the IPO price of ₹195.

According to the grey market activities observed over the last 11 sessions, the current GMP is ₹2, indicating a downward trend. The minimum GMP noted is ₹0.00, while the maximum reached is ₹36, as per expert analysis.

‘Grey market premium‘ indicates investors’ readiness to pay more than the issue price.

Also Read | Wakefit Innovations IPO day 3: GMP, subscription status to review. Apply or not?
Wakefit IPO

Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.



Source link

You Might Also Like

Stock market today: Sensex ends over 1,100 points higher from day’s low; Nifty 50 near 23,650 | Stock Market News

FPIs sell over ₹2 lakh crore in Indian stock market so far in 2026. Are they driving the boom-and-bust cycle? | Stock Market News

Small-cap stock under ₹50: Promoter-backed DII hold stake in tech stock in Q4FY26 despite selloff on D-Street | Stock Market News

Coforge to Tech Mahindra: Tech stocks extend rally for second session; Nifty IT jumps over 2% | Stock Market News

Indian bond yields spike to six-week high as crude oil price rally jolts markets | Stock Market News

TAGGED:Corona Remedies IPOcorona remedies ipo gmpGrey market premiumIPOsNephrocare ipoNephrocare ipo gmpWakefit Innovations IPOWakefit Innovations IPO GMP
Share This Article
Facebook Twitter Email Print
Previous Article Anand Rathi turns bullish on this mid-cap tech stock after 25% crash from recent highs, upgrades to ‘Buy’ | Stock Market News
Next Article 350% rally in five years! Multibagger small-cap stock jumps 10.5% today; rallies over 27% in 2 sessions; here’s why | Stock Market News

We influence 20 million users and is the number one business and technology news network on the planet.

Find Us on Socials

News for IndiaNews for India
© Wealth Wave Designed by Preet Patel. All Rights Reserved.
  • BUSINESS